investors.shire.com
Shire: Investor RelationsShire - Investor Relations
http://investors.shire.com/
Shire - Investor Relations
http://investors.shire.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
4.7 seconds
16x16
PAGES IN
THIS WEBSITE
18
SSL
EXTERNAL LINKS
104
SITE IP
54.230.195.46
LOAD TIME
4.656 sec
SCORE
6.2
Shire: Investor Relations | investors.shire.com Reviews
https://investors.shire.com
Shire - Investor Relations
investors.shire.com
Shire: Our Strategy
http://investors.shire.com/our-strategy.aspx
Skip to main content. Annual and Interim Reports. Annual and Interim Reports. Excellence in ADHD Patient Group Awards 2016. RESEARCH AND EDUCATIONAL GRANTS. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. We drive performance from our currently marketed products to optimize revenue growth and cash generation. Prepare for approval and launch of lifitegrast (...
Shire: Dividends
http://investors.shire.com/shareholder-information/dividends.aspx
Skip to main content. Annual and Interim Reports. Annual and Interim Reports. Excellence in ADHD Patient Group Awards 2016. RESEARCH AND EDUCATIONAL GRANTS. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. The current dividend is the 2016 first interim dividend, details of which are:. Sep 8, 2016. Sep 9, 2016. Oct 7, 2016. View our dividend growth chart.
Shire: Analysts
http://investors.shire.com/analysts.aspx
Skip to main content. Annual and Interim Reports. Annual and Interim Reports. Excellence in ADHD Patient Group Awards 2016. RESEARCH AND EDUCATIONAL GRANTS. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. UK and European Analysts. Tel: 020 7425 6647. 1 Great Winchester Street. Tel: 020 7545 0470. Merrill Lynch Financial Centre. 2 King Edward Street. Royal B...
Shire: Presentations and Webcasts
http://investors.shire.com/presentations-and-webcasts/year-2015.aspx
Skip to main content. Annual and Interim Reports. Annual and Interim Reports. Excellence in ADHD Patient Group Awards 2016. RESEARCH AND EDUCATIONAL GRANTS. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Dec 01, 2015. Piper Jaffray 27th Annual Healthcare Conference. Nov 02, 2015. Shire to Acquire Dyax Corp. Oct 23, 2015. Third Quarter 2015 Results. By foll...
Shire: Annual and Interim Reports 2015
http://investors.shire.com/annual-and-interim-reports/year-2015.aspx
Skip to main content. Annual and Interim Reports. Annual and Interim Reports. Excellence in ADHD Patient Group Awards 2016. RESEARCH AND EDUCATIONAL GRANTS. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Annual and Interim Reports. Aug 05, 2016. Jul 30, 2015. Mar 26, 2015. Annual Report for the year ended December 31, 2014.
TOTAL PAGES IN THIS WEBSITE
18
Shire: Patient Services, Assistance & Product Support
http://www.shire.at/patients/patient-services
Transparenz und ethische Standards. Unsere Positionen im Dialog mit Stakeholdern. Service für Patienten. Hier finden Sie die Kontaktdaten von Patientenorganisationen, die Ihnen weiterhelfen werden. Shire unter die 100 nachhaltigsten Unternehmen weltweit gewählt. Shire ist führend im Bereich soziale Verantwortung. Erfahren Sie mehr über unser Engagement. BLEIBEN SIE MIT UNS IN KONTAKT. Melden Sie sich für E-Mail und SMS-Benachrichtigungen an. Möchten Sie uns Feedback zu unserer Webseite geben?
Shire: Unsere Unternehmenskultur
http://www.shire.at/who-we-are/our-story/our-culture
Transparenz und ethische Standards. Unsere Positionen im Dialog mit Stakeholdern. Lesen Sie unseren CSR-Bericht. Erfahren Sie mehr über unser Engagement im Bereich soziale Verantwortung. Werden Sie Teil unseres Teams. Wir suchen stets qualifizierte Fachkräfte zur Verstärkung unseres Teams. BLEIBEN SIE MIT UNS IN KONTAKT. Melden Sie sich für E-Mail und SMS-Benachrichtigungen an. Möchten Sie uns Feedback zu unserer Webseite geben?
Über Shire: Kooperationen
http://www.shire.at/who-we-are/how-we-operate/partnerships
Transparenz und ethische Standards. Unsere Positionen im Dialog mit Stakeholdern. EINE KLARE STRATEGIE ZUR WEITERENTWICKLUNG UNSERES GESCHÄFTS. Wir sind fortlaufend auf der Suche nach Kooperationspartnern und Zukäufen sowie Lizenzierungsmöglichkeiten, um Innovationen für die Patienten weiter voranzutreiben. Wir bemühen uns, unsere Pipeline weiter zu stärken und um angrenzende Therapiegebiete zu erweitern. Bei unseren Bemühungen steht der Patient im Mittelpunkt. BLEIBEN SIE MIT UNS IN KONTAKT.
Über Shire: Transparenzauskunft
https://www.shireswitzerland.ch/who-we-are/how-we-operate/transparency-disclosures
Transparenz und ethische Standards. Unsere Positionen im Dialog mit Stakeholdern. UNSER ENGAGEMENT FÜR PATIENTEN. Über unser Engagement für Patienten. Transparenz und ethische Standards. Der Europäische Dachverband der nationalen Verbände forschender Pharmaunternehmen (EFPIA, European Federation of Pharmaceutical Industries and Associations, http:/ www.efpia.eu/. Shire unterstützt die von der EFPIA formulierten Transparenz-Grundsätze, befolgt die nationalen Offenlegungsanforderungen und ist ste...Der Eur...
Shire: Der Unternehmensverantwortung verpflichtet
https://www.shireswitzerland.ch/who-we-are/responsibility
Transparenz und ethische Standards. Unsere Positionen im Dialog mit Stakeholdern. UNSER ENGAGEMENT FÜR PATIENTEN. Über unser Engagement für Patienten. Shire entwickelt bahnbrechende Therapien für Menschen mit seltenen und komplexen Erkrankungen. Lesen Sie hier den 2015 Responsibility Review (CSR-Bericht). Brief von Flemming Ornskov, Shire CEO. Wir sind stolz auf den Fortschritt, den wir machen. Wir freuen uns sehr, dass unsere Bemühungen, noch verantwortungsbewusster zu handeln, auch von der Öffentlichke...
TOTAL LINKS TO THIS WEBSITE
104
SGI - Investor Relations
The Trusted Leader in High Performance Computing. Contact Sales ». Annual Reports and Proxies. Silicon Graphics International Corp. Read More ». August 05, 2015. SGI Reports Fourth Quarter and Fiscal Year 2015 Financial Results. July 30, 2015. SGI Japan Installs Five-Screen Virtual Reality System at Komatsu, Oyama. View all releases ». Financial Events and Presentations. August 11, 2015. Oppenheimer 18th Annual Technology, Internet and Communications conference. View all events and presentations ».
SharpSpring Investors
SharpSpring, Inc. (NASDAQ: SHSP) is a global provider of marketing technologies. And www.sharpspringmail.com. Steven Huey Joins SharpSpring Board of Directors. December 23, 2016. SharpSpring Leaps to #2 In Agency Market Share per 2016 Mirren-RSW/US Report. December 19, 2016. SharpSpring to Present at the LD Micro Main Event on December 7, 2016. November 29, 2016. SharpSpring Ranked Number 391 Fastest-Growing Company in North America on Deloitte’s 2016 Technology Fast 500. November 16, 2016. Definitive Pr...
Shawbrook Group plc
Shawbrook is a specialist UK savings and lending bank founded in 2011 to serve the needs of SMEs and individuals in the UK with a range of lending and saving products. At 30 June 2015 our total lending reached more than 2.7 billion and we have now raised more than 2.6 billion in deposits since our launch. Latest result download links. Half year results for 2015. Half year results for 2014.
investors.sherwin-williams.com
Investor Relations - Sherwin-Williams
Skip to main content. Sherwin-Williams has been in business since 1866. The Companys core business is the manufacture, distribution and sale of coatings and related products. Sherwin-Williams has annually increased dividends since 1979. Recent Stock Split History. Access Proxy Materials Online. Sections of our site. 2017 The Sherwin-Williams Company. Politique de confidentialité. CA Supply Chains Act.
Investor Relations - Sherwin-Williams Investor Relations
Skip to section navigation. Sherwin-Williams has been in business since 1866. The Company's core business is the manufacture, distribution and sale of coatings and related products. Sherwin-Williams has annually increased dividends since 1979. SEC Section 16 Filings. Recent Stock Split History. Access Proxy Materials Online. Browse Our Coating Sites. 2015 The Sherwin-Williams Company. Politique de confidentialité. CA Supply Chains Act.
Shire: Investor Relations
Skip to main content. With life-altering conditions to lead better lives. Annual and Interim Reports. Shire Proposed Combination With Baxalta. With life-altering conditions to lead better lives. Annual and Interim Reports. Excellence in ADHD Patient Group Awards 2015. RESEARCH AND EDUCATIONAL GRANTS. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Annual and Interim Reports. Shire proposed combination with Baxalta. Research and Development day. Jul 30, 2...
Shopify - Home
August 14, 2015. August 14, 2015. July 30, 2015. Shopify Announces Second-Quarter 2015 Financial Results. No items found for this year. August 11, 2015. Pacific Crest 17th Annual Global Technology Leadership Forum. Latest Quarter - Financial Report. Fourth quarter Transcript (PDF 4 KB. Test Q4 2015 Transcript (PDF 4 KB. Founder, Chief Executive Officer. These underlying aspirations and values drive our mission: make commerce better for everyone. I hope you’ll join us. Large and Growing Opportunity. Engag...
Signal Genetics™ | ABOUT | Investors
How Can MyPRS™ Help? Insurance and Payment Information. Signal Genetics is a commercial stage, molecular diagnostic company helping physicians make better-informed decisions concerning the care of their patients suffering from multiple myeloma (MM) through our flagship product Myeloma Prognostic Risk Signature, or MyPRS. Our mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Day High: 1.49. Day Low: 1.32. Aug 17, 2015. Aug 12, 2015.
investors.silverbayrealtytrustcorp.com
Silver Bay Realty Trust Corp.
As of August 17, 2015 -. Minimum 20 minute delay. Q2 2015 Earnings Conference Call. Thursday, August 6th, 2015. Silver Bay Realty Trust Corp. Silver Bay Realty Trust Corp. Reports Second Quarter 2015 Financial Results. Silver Bay Realty Trust Corp. Announces Earnings Release and Conference Call for Second Quarter 2015 Financial Results. Silver Bay Realty Trust Corp. Announces Second Quarter 2015 Dividend of $0.12 per Share. Silver Bay Realty Trust Corp. Reports First Quarter 2015 Financial Results.
SIMON | Investor Relations | Corporate Overview
Annual Reports on Form 10-K. Quarterly Reports on Form 10-Q. Code of Business Conduct. Stockholder Info and Events. Stockholder Info and Events. Archived Events and Presentations. Simon Announces Opening Of Gloucester Premium Outlets and Expansion Of San Francisco Premium Outlets. Simon Announces Renovation Plans For Retail Component Of Copley Place. Simon Property Group Sells $1.1 Billion Of Senior Notes. 2nd Quarter 2015 Supplemental Information. 2nd Quarter 2015 10-Q. 160; 0.93. As of 08/14/15. Harva...
IRWeblink
Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.
SOCIAL ENGAGEMENT